US Secondary Hyperparathyroidism Treatment (SHPT) Market Size, Share, Growth Analysis, By Drug Analysis(hospital & retail pharmacies, online channel, and other), By Region - Industry Forecast 2024-2031

Geographically, the West, Midwest, South, and Northeast areas make up the U.S. SHPT therapy market. The South region brought in USD 1.93 billion in revenue and is expected to take the lead in the US market over the next several years. The South region's dominance can be attributed to the existence of a large number of dialysis facilities and the strategic positioning of top dialysis clinic networks like Fresenius Care, DaVita, etc. in the area. Additionally, due to the high incidence of older people with kidney disorders, the southern region of the United States has the highest prevalence of secondary hyperparathyroidism.

A significant percentage of individuals with SHPT are identified in states like Iowa and South and North Dakota, which is a major contributing element to the Midwest region's second-place ranking in the US. SHPT therapy market. In the Midwest region, SHPT affects 90% of individuals with stage-5 CKD (ESRD), according to the Centers for Disease Control and Prevention (CDC). This sizable patient base is anticipated to accelerate the market expansion for SHPT treatment over the forecast period. It is predicted that the Northeast region of the U.S. SHPT market will expand at a faster CAGR throughout the forecasted period due to the enhanced reimbursement environment in the United States.